When evaluating a patient with suspected acute hepatitis B, the most direct diagnostic approach is to correlate serologic markers with biochemical evidence of liver injury. The hallmark of acute infection is the detection of hepatitis B surface antigen (HBsAg) in serum, which appears 1–10 weeks after exposure and precedes symptom onset. This must be paired with an elevated alanine aminotransferase (ALT) level, confirming hepatocyte damage. A typical ALT elevation in acute viral hepatitis exceeds 10 times the upper limit of normal, often peaking above 1000 IU/L.
During the window period (after HBsAg clears but before anti-HBs appears), IgM anti-HBc may be the only detectable marker. Anti-HBs alone with normal ALT indicates resolved infection or vaccination. Isolated anti-HBc IgG suggests past exposure. HBeAg is a marker of high viral replication and infectivity but is not used alone for initial diagnosis. In high-risk patients with prodromal symptoms, prompt serologic testing guides isolation precautions and consideration of antiviral therapy if severe or prolonged.
Nursing priorities include monitoring for complications such as fulminant hepatitis, coagulopathy, and encephalopathy, while providing supportive care and education on transmission prevention.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.